Most of the drugs administered to stone patients appear to be inappropriate and doing more harm than good to the patients. The objective of this paper is to identify the prevalence of blind chemotherapy among the stone patients and find out the real indication for the drugs administered. Patients who attended the stone clinic for the first time were interviewed to find out what drugs they had been taking before the attendance at the stone clinic. 350 patients consuming specific drugs relevant to stone formation at least for a period of 15 days were selected for a detailed assessment.
The Journal of the Association of Physicians of India
OBJECTIVE: Renal calculus disease is associated with recurrence after its surgical removal in large number of cases. Kulattha is acclaimed to have litholytic property in ayurvedic literature. We decided to compare the litholytic property of Kulattha with potassium citrate, an agent used to reduce stone recurrence in modern medicine. METHODS: Forty seven patients with diagnosis of calcium oxalate renal calculi were taken in study. Twenty four patients received Kulattha (Group I) and 23 patients were given potassium citrate(Group II) for a period of 6 months.
Chitosan and alkalinizing agents can decrease morbidity and mortality in humans with chronic kidney disease (CKD). Whether this holds true in dog is not known. Objective of the study was to determine whether a commercial dietary supplement containing chitosan, phosphate binders, and alkalinizing agents (Renal), compared to placebo, reduces mortality rate due to uremic crises in dogs with spontaneous CKD, fed a renal diet (RD). A masked RCCT was performed including 31 azotemic dogs with spontaneous CKD.